Herantis: Submitted Clinical Trial Application (CTA) - Redeye

Redeye endorses today’s news that Herantis has submitted a clinical trial application for a phase I study with its lead candidate HER-096 targeting Parkinson’s disease. Herantis reiterates its guidance to initiate the study in H1 2023, pending approval. We will return with a research update in early January to discuss the study in-depth.

Länk till analysen i sin helhet: https://www.redeye.se/research/869366/herantis-submitted-clinical-trial-application-cta?utm_source=finwire&utm_medium=RSS